My first PhD paper is published! We outline how price negotiations can introduce interactions to economic evaluations – failure to account for them can lead to incorrect conclusions about cost-effectiveness 1/2 https://t.co/TwPg0DPpwj
@lauraontweets@CHeDS_ie@INFO_NCPE
Delighted to accept this award with @KieranWalshMPSI on behalf of all the co-authors in @HIQA, NIAC and beyond. You can read our paper here https://t.co/8Vn5DGCmKh
🌟 Congratulations to Kieran Walsh & Helen O’Donnell, winners of the Community & Social Care Award at the 2024 HSE Library Open Access Research Awards! 🎉 Explore their rapid review on COVID-19 immunity: https://t.co/cTY3gV2lIJ #hselibrary @aalawton @JdaDrennan @CcoHse@LenusHSE
We have published our third HTA and evidence synthesis bulletin of the year. Our bulletin summarises the findings of our reports, upcoming publications and launches. Read the bulletin here: https://t.co/UAm2wkgmMy
We have published our Health Technology Assessment (HTA) on the repatriation of paediatric haematopoietic stem cell transplant (HSCT) services to Ireland for children with rare inherited conditions. You can find out more here: https://t.co/eRw64WpQJM
Exciting #ResearchFellow opportunity: The NCPE & @TrinityMed1 seek a suitable candidate to work with the HEALED Consortium on #TILtherapies to undertake the #HTA research package. (Find further info at: https://t.co/mcSRR4QMAf & search for 'HEALED’).
#ThisIsTrinityMed#JobFairy
Dr Helen O'Donnell, a Senior HTA analyst and registered pharmacist with a background in health economics (MSc) and pharmacoeconomics (PhD), uses her clinical, economic and statistical expertise to examine the evidence supporting new health interventions in HIQA.
It has been a difficult and disappointing week for many, as the rise to dominance of the delta variant has delayed plans for wider reopening; but the likely impact of delta is stark, and caution is well advised. 1/36
The Beneluxa collaboration @BeneluxaCoop has issued a joint statement with the Nordic Pharmaceutical Forum. This statement reiterates the importance of cost effectiveness in the assessment of value for medicines
https://t.co/CDrqbY1kbu
Our final webinar takes place next Tuesday 27th April! Topics include Health Technology Management, the Benaluxa process and drugs for Rare Diseases. Full program and booking information available here: https://t.co/9juPtPioGx
Our Applicant Rapid Review Template has been updated. Until March 31st, submissions using the old (v1.5) or new template (v2.0) will be accepted. From April 1st, applicants must use the new template (v2.0). For more information click here: https://t.co/uqYpK444g7
Our second webinar begins this morning at 10am!
Follow the hashtag #NCPE2021 to see highlights from todays presentations. Attendees can ask questions of our panelists via the zoom Q and A function.
Our next webinar takes place next Tuesday 16th March! Topics include the incorporation of clinical opinion and expert elicitation into economic evaluations and "cure" implications for HTA. Full program and booking information available here: https://t.co/EBEXjxIth1
Thanks to everyone who attended our webinar today. Our next session takes place on 16th March. You can still register at https://t.co/EBEXjxIth1 #NCPE2021
Our first Speaker Prof Michael Barry @INFO_NCPE talks about Health Technology Management and the increasing importance of conditional positive recommendations #NCPE2021
Our webinar series starts this morning at 10am! Looking forward to hearing about the latest developments in pharmacoeconomics in Ireland.
Use the hashtag #NCPE2021
⏰Don't forget our webinar series starts tomorrow! Find out about the latest updates in the rapid review and HTA process and updates on European pharmaceutical strategy. Register here: https://t.co/EBEXjxIth1